ACM
MRTX

Atika Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Atika Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Hold
0
– -$1.29M – 109
2019
Q4 		– Hold
0
– – – 68

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Atika Capital Management's MRTX Position: Q2 2021 in Review

Atika Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 34,000 shares — an estimated $5.82M sold.

Atika Capital Management first reported a position in MRTX in Q2 2019 and held it in 4 quarters. The position peaked at $10.4M in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • Atika Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Atika Capital Management sold 34,000 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $5.82M.
  • Atika Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
  • Atika Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $10.4M in Q4 2020.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Atika Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.